1 Apuri S.Neoadjuvant and adjuvant therapies for breast cancer[J].South Med J,2017,110(10):638-642. 2 周星彤,沈松杰,孙强.中国乳腺癌筛查现状及进展[J].中国医学前沿杂志(电子版),2020,12(3):6-11. 3 Li F,Ma L,Geng C,et al.Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors[J].Pathol Res Pract,2018,214(8):1166-1172. 4 刘欢.乳腺癌新辅助化疗前后分子生物学指标变化及预后分析[D].石家庄:河北医科大学,2018. 5 叶京明,刘荫华.2017年NCCN乳腺癌临床实践指南(第3版)更新与回顾[J].中华医学杂志,2018,98(18):1377-1379. 6 Parinyanitikul N,Lei X,Chavez-Macgregor M,et al.Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes[J].Clin Breast Cancer,2015,15(2):153-160. 7 Li L,Han D,Wang X,et al.Prognostic values of Ki-67 in neoadjuvant setting for breast cancer:a systematic review and meta-analysis[J].Future Oncol,2017,13(11):1021-1034. 8 刘伟,王燕荣,王永兴.新辅助化疗后的病理完全缓解及其对不同分子亚型乳腺癌的预后价值[J].现代肿瘤医学,2018,26(13):2118-2122. 9 Denkert C,Von Minckwitz G,Darb-Esfahani S,et al.Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer:a pooled analysis of 3771 patients treated with neoadjuvant therapy[J].Lancet Oncol,2018,19(1):40-50. 10 吴晶晶,张妍,林琳,等.ER和PR阴性乳腺癌雄激素受体与HER2表达相关性及其临床意义[J].中华肿瘤防治杂志,2016,23(23):1544-1549. 11 Hirata T,Shimizu C,Yonemori K,et al.Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer[J].Br J Cancer,2009,101(9):1529-1536. 12 李国政,庞达.HER2阳性乳腺癌治疗的研究进展[J].实用肿瘤学杂志,2020,34(1):74-78. 13 Yoshida A,Hayashi N,Suzuki K,et al.Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer[J].J Surg Oncol,2017,116(8):1021-1028. 14 Tao M,Chen S,Zhang X,et al.Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer:A meta-analysis[J].Medicine,2017,96(51):e9384. 15 Lee J,Im YH,Lee SH,et al.Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer[J].Cancer Chem Pharm,2008,61(4):569-577. 16 Matsubara N,Mukai H,Fujii S,et al.Different prognostic significance of Ki-67 change between pre-and post-neoadjuvant chemotherapy in various subtypes of breast cancer[J].Breast cancer Res Treat,2013,137(1):203-212. 17 Samuel O,Olayide A,Ganiyu R,et al.Relationship between tumour size and response to neoadjuvant chemotherapy among breast cancer patients in a tertiary center in Nigeria[J].Malawi Med J,2018,30(1):13-16. 18 Wu SG,Li Q,Zhou J,et al.Using the lymph node ratio to evaluate the prognosis of stage Ⅱ/Ⅲ breast cancer patients who received neoadjuvant chemotherapy and mastectomy[J].Cancer Res Treat,2015,47(4):757-764. |